

Abstract

A new administration regimen giving an extended plasma concentration profile of a H⁺, K⁺-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H⁺, K⁺-ATPase with 0.5 - 4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.